🇺🇸 FDA
Patent

US 10544392

Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood

granted A61KA61K2239/57A61K38/1703

Quick answer

US patent 10544392 (Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2239/57, A61K38/1703, A61K40/11, A61K40/32